TrialSignal
Clinical trial intelligence report
A Phase 1b Trial of ARV-471 in Combination With Everolimus in Patients With ER+, HER2- Advanced or Metastatic Breast Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Aug 04, 2026
Report code
NCT05501769-Aug 04, 2026
NCT ID
NCT05501769
Status
COMPLETED
Phase
PHASE1
Sponsor
Arvinas Estrogen Receptor, Inc.
Executive brief
Investment-Ready Snapshot
A Phase 1b Trial of ARV-471 in Combination With Everolimus in Patients With ER+, HER2- Advanced or Metastatic Breast Cancer is a PHASE1 clinical asset sponsored by Arvinas Estrogen Receptor, Inc. in Breast Cancer. SEO and diligence focus: ARV-471 in combination with Everolimus, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05501769
Indication
Breast Cancer
Modality
combination therapy
Target
ARV-471 in combination with Everolimus
Intervention
ARV-471 in combination with Everolimus
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.